VA as follow-up treatment after stem cell transplant for leukemia or MDS
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether giving a drug called VA (which includes a vitamin A derivative and a medication that helps the immune system fight cancer) after a stem cell transplant can help keep leukemia or MDS from coming back. It is for patients who are already in remission after their transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have been diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- You must have already had a stem cell transplant (also called a bone marrow transplant).
- Before starting the study, your blood counts must be in remission, meaning you have very few or no cancer cells in your bone marrow.
- You must not have an active infection or serious medical condition that is not under control.
- If you are pregnant or breastfeeding, you cannot take part in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
This study tests whether giving two drugs, decitabine and venetoclax, after a stem cell transplant can help keep your blood cancer from coming back. It is for people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or MDS/AML who have had or will have a stem cell transplant.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This study tests whether adding venetoclax (a targeted pill that helps kill leukemia cells) to a stem cell transplant, and continuing it afterward, improves outcomes compared to a placebo. It is for people with acute myeloid leukemia (AML) in their first remission who are getting a reduced-intensity transplant.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.